On May 3, 2023 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL (Press release, Innate Pharma, MAY 3, 2023, View Source [SID1234630956]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
One abstract for SAR’579, currently developed by Sanofi, has been selected for oral presentation. SAR’579 is a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123 using Innate’s proprietary multi-specific antibody format ANKET.
Two abstracts with monalizumab in non-small cell lung cancer clinical trials led by AstraZeneca have been accepted for trial in progress posters.
ASCO abstract title details:
SAR’579 / IPH6101
Abstract: 7005
Abstract Title: A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Session Type/Title: Oral Abstract Session – Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: 6/2/2023, 1:00 PM – 4:00 PM
Monalizumab
Abstract: TPS8610 Poster Bd# 231b
Abstract Title: Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
Session Type/Title: Poster Session – Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Date and Time: 6/4/2023, 8:00 AM EDT
Abstract: TPS8604 Poster Bd# 228b
Abstract Title: NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
Session Type/Title: Poster Session – Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Date and Time: 6/4/2023, 8:00 AM EDT
According to ASCO (Free ASCO Whitepaper) Annual Meeting, full abstracts will become public at 5:00 PM EDT on May 25, 2023. More details about the programs for the ASCO (Free ASCO Whitepaper) Annual Meetings are available online at www.asco.com
About ANKET
ANKET (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.